Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

Abstract Background Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epacadostat is a selective inhibitor of indoleamine 2,3...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, Mehmet Artac, Martín Lázaro Quintela, Jong-Seok Lee, Maen Hussein, Miklos Pless, Luis Paz-Ares, Lance Leopold, Jeannie Daniel, Mihaela Munteanu, Ayman Samkari, Lu Xu, Charles Butts
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2024-07-01
Rangatū:	BMC Cancer
Ngā marau:	Epacadostat Combination immunotherapy Non-small cell lung cancer Pembrolizumab PD-L1 high
Urunga tuihono:	https://doi.org/10.1186/s12885-023-11203-8
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!